(NASDAQ:ELAB), Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio's classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity. Phase […]

(NASDAQ:BENF), DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the “Board”) has appointed Peter T. Cangany Jr. as Chairman of the

(NasdaqGM:NKLR), NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors today announced continued substantive progress in the licensing of its SOLO(TM) Micro-Modular Reactor (MMR) through active engagement with the U.S. Nuclear Regulatory Commission (NRC), reinforcing the company's position at

(NasdaqGM:HBIO), Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it

(NasdaqGM:ACRV), WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed

(TSX:BBD-A),(TSX:BBD-B),(OTC US:BDRBF),(Other OTC:BDRBF), MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — Bombardier today confirmed the company is on track to reach its previously stated net leverage ratio target of 2.0-2.5x. With the $500 million debt redemption notice announced on December 17, which is expected to close by Feb 17, 2026, the Bombardier team will have successfully

(NASDAQ:WRAP), MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or the “Company”), a global leader in non-lethal response and public-safety technology solutions, today announced that the Alliance Police Department (“Alliance PD”) has partnered with Wrap to purchase and deploy BolaWrap(R) 150 devices across the department and is expected to become

(NASDAQ:CMPX), BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability:

(NASDAQ:XAIR), GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for

(NYSE:FCN), WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Dr. Xi Chen, Professor and Andre Meyer Faculty Fellow at the Department of Technology, Operations and Statistics at the New York University Stern School of Business, has affiliated with its subsidiary Compass Lexecon. Dr. Chen, who is based in